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ABSTRACT 
Childhood onset schizophrenia is a rare disorder whose prognosis is generally worse than 
that in the adult onset type of schizophrenia. Conventional neuroleptics have yielded inconsistent 
results with the risk of exposing the child to extrapyramidal and cognitive adverse effects which 
could interfere with proper development of the child. Effective and safe use of clozapine in children 
with schizophrenia has been reported. This drug is recently introduced in India and reports of its 
use in children are yet to come from this part of the world. This case report is on the effective and 
safe use of clozapine in a girl child with schizophrenia who became ill at 9 years of age. 
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The onset of schizophrenia is most often 
in the fate adolescence or later but it can start 
rarely during childhood. The disorder is seen in 
0.1 to 1 % of children (Remschmidt et al., 1994). 
Very early onset patients only partially benefit 
from conventional antipsychotic treatment and 
are at increased risk for developing tardive 
dyskinesia (T.D) (Mozes et al., 1994). 
Clozapine has been shown to be effective in 
childhood-onset schizophrenia, especially in 
treatment resistant cases and in those 
intolerant to the typical neuroleptics (Frazier 
et al., 1994; Remschmidt et al., 1994). 
Clozapine is now available in India and 
its use in children is yet to be reported. We 
report here the successful use of clozapine in 
a girl who had schizophrenia starting at the age 
of nine years. 
CASE REPORT 
Ms. A, a 9 year old girl was brought by 
her parents in May 1995 with the complaints 
that for the past 4 months she had been 
behaving differently with other children in the 
form of picking up quarrels and pinching and 
pushing them. Her academic performance was 
unchanged and there were no reports about any 
abnormal behaviour from the school. Her sleep, 
eating habits and self-care activities were 
normal. The child at this point of time was seen 
to be over active to talk like adults in accent 
and in the words used. A psychometric 
evaluation showed no abnormality in her 
psychological functioning and there was no 
evidence for any organicity. The child was talked 
to about the complaints regarding her from 
others which she said were baseless. No 
psychiatric diagnosis nor any intervention was 
made at this consultation. 
The parents reported in November 1995 
that Ms A had shown a sudden change in her 
behaviour for the preceding 2 weeks. She had 
become very inattentive towards her studies and 
had wandered away from home once. She had 
become more restless and had not been 
sleeping well. The day before they consulted, 
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the child had attempted to set fire to some 
clothes in the bedroom for no apparent reason. 
She was not sent to school for a week as 
- she tended to wander away from school. She 
showed no interest at all in any academic or 
other activities at home. On examination at this 
time the girl was restless and irritable. She was 
unkempt and her emotional response was poor. 
She was disinhibited and talked about sexual 
matters. Her talk was incomprehensible at 
times. Her affect was flat. She reported audi-
tory hallucinations in the form of hearing voices 
which were telling her stories. She also had 
visual hallucinations in the form of people 
performing magic before her to entertain her. 
These group of people, she said, generally kept 
a watch on where she was going with a radio 
and used it to communicate with her. She scored 
23 on the BPRS (Overall & Gorham, 1988) at 
this interview, Detailed neurological evaluation 
including an EEG and CAT scan of the brain 
revealed no abnormality. A diagnosis of 
schizophrenia (ICD-10, WHO, 1992) was made. 
She developed extrapyramidal 
symptoms with haloperidol and a trial of 
chlorpromazine led to intense drowsiness and 
giddiness on standing therefore she was put on 
trifluoperazine which was increased upto 25 mg 
which led to reduction in her overactive, 
disinhibited behaviour, and improved her sleep. 
The hallucinations persisted and she continued 
to refer to the group of people following her. 
Her poor self-care, formal thought 
disorder and the flat affect persisted. She could 
not be sent to school as she was very dull most 
of the time and showed little interest in any 
activity. This status continued for the next 8 
weeks. Her BPRS score remained at 17 after 
the initial improvement. 
In view of the lack of progress in her 
response to the treatment, clozapine was started 
in February 1996 after the required 
prerequisite evaluations. At the end of two 
weeks she was completely withdrawn from 
trifluoperazine and the dosage of clozapine 
reached 100 mg/day. A maximum dose of 200 
mg/day was reached in 4 weeks time and was 
maintained for 8 weeks. By the end of 3 months 
of treatment with clozapine the BPRS score 
came down to 7 with a palpable change in her 
affective responses. Her thought process was 
clear and the overactivity and restlessness were 
not observed. She began to show interest in 
going back to school and in attending informal 
classes in classical music. The parents were 
hesitant to put her in a special school meant for 
children with learning disability and other 
academic difficulties in the city after the school 
accepted to take up Ms. A on a trial basis. 
Ms. A has been attending this school for 
the past 12 months during which she has shown 
steady and progressive changes in her 
academic and social activities. She also showed 
keen interest and participated in sports, 
dramatics and other extracurricular activities at 
the school. It is planned to put her back in the 
regular school from the next academic year. The 
score on the BPRS remained between 7 and 9 
throughout the follow-up period. 
After the 2 months of clozapine therapy 
she exhibited some side-effects of the drug in 
form of sialorrhoea, daytime drowsiness and 
slurring of speech. These were managed by 
giving the maximum dose at night, and adding 
2 mg of trihexyphenidyl/day. Attempts at 
reducing the dosage of clozapine were followed 
by return of overactivity, disinhibition, 
inattention, aggressiveness and insomnia. 
Granulocyte counts remained within normal 
limits throughout the treatment period. 
DISCUSSION 
The mean age at diagnosis of 
childhood-onset schizophrenia was reported to 
be between the ages of 9 and 10 years. The 
onset was very often insidious with a 
predominance of boys and the symptoms 
frequently included flat affect and visual 
hallucinations (Asarnowet al., 1994). The case 
reported here fitted these general descriptions 
but for the sex of the patient. 
Typical neuroleptics like haloperidol, 
loxapine, pimozide, thiothixene have been used 
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in childhood onset schizophrenia with positive 
results (Spencer & Campbell, 1994). However 
the risk for developing extrapyramidal 
symptoms including T.D. are more with the 
typical neuroleptics compared to clozapine. It 
has also been shown that chronic treatment with 
typical neuroleptics may impair cognitive 
functions (Lee et al., 1994). The adverse 
motor and cognitive effects of typical 
neuroleptics are of crucial importance in 
childhood as they could interfere with proper 
motor and cognitive development of the child. 
Clozapine with its reduced risk for producing 
T.D. (Tamminga et al., 1994) and better 
efficacy in ameliorating cognitive dysfunctions 
(Lee et al., 1994) is thus ideally suited for use 
in children with schizophrenia. 
This case report shows effective and 
safe use of clozapine in childhood-onset 
schizophrenia following the recommended 
precautions. 
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